159 164

Cited 7 times in

Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment

DC FieldValueLanguage
dc.contributor.author민유홍-
dc.date.accessioned2015-04-23T17:16:32Z-
dc.date.available2015-04-23T17:16:32Z-
dc.date.issued2010-
dc.identifier.issn0368-2811-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/102153-
dc.description.abstractOBJECTIVE: The purpose of this study was to re-evaluate post-remission therapy outcomes after first remission according to years of patient enrollment in patients with core binding factor acute myeloid leukaemia. METHODS: We conducted a retrospective study on 138 patients aged less than 60 years diagnosed with core binding factor acute myeloid leukaemia between 1994 and 2006, comparing allogeneic stem cell transplantation and high-dose cytarabine chemotherapy as post-remission treatment options after the first remission. RESULTS: The 5-year probabilities of disease-free survival and overall survival were not different between allogeneic stem cell transplantation and high-dose cytarabine groups. However, 3-year probabilities of disease-free survival (86.7% vs. 67.0%) and overall survival (90.0% vs. 67.3%) showed a trend towards improvement in the allogeneic stem cell transplantation group compared with the high-dose cytarabine group in cohort after 2003 (2003-2006), whereas outcomes were not different in cohort before 2003 (1994-2002). Especially, 3-year probabilities of disease-free survival (95.2% vs. 59.3%, P = 0.008) and overall survival (95.2% vs. 59.6%, P = 0.032) of allogeneic stem cell transplantation group were significantly better than high-dose cytarabine group in cohort after 2003 of acute myeloid leukaemia patients with t(8;21). The relative risk of overall survival with allogeneic stem cell transplantation, compared with high-dose cytarabine chemotherapy, was significantly improved in the cohort after 2003 (0.33; 95% CI, 0.07-1.48) when compared with that before 2003 (1.92; 95% CI, 0.77-4.82). In multivariate analysis in cohort after 2003, allogeneic stem cell transplantation as post-remission therapy was associated with better disease-free survival. CONCLUSIONS: Allogeneic stem cell transplantation is currently the more effective post-remission therapy than it was prior to 2003 for core binding factor acute myeloid leukaemia achieving first remission. On the contrary to previous findings, allogeneic stem cell transplantation provides significantly improved outcomes than high-dose cytarabine chemotherapy in acute myeloid leukaemia with t(8;21).-
dc.description.statementOfResponsibilityopen-
dc.format.extent556~566-
dc.relation.isPartOfJAPANESE JOURNAL OF CLINICAL ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdolescent-
dc.subject.MESHAdult-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/administration & dosage-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use-
dc.subject.MESHCohort Studies-
dc.subject.MESHCore Binding Factors/metabolism*-
dc.subject.MESHCytarabine/administration & dosage-
dc.subject.MESHCytarabine/therapeutic use-
dc.subject.MESHDaunorubicin/administration & dosage-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLeukemia, Myeloid, Acute/metabolism-
dc.subject.MESHLeukemia, Myeloid, Acute/mortality-
dc.subject.MESHLeukemia, Myeloid, Acute/therapy*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHRemission Induction-
dc.subject.MESHStem Cell Transplantation-
dc.subject.MESHSurvival Rate-
dc.subject.MESHYoung Adult-
dc.titleRe-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorHo-Jin Shin-
dc.contributor.googleauthorHyeoung-Joon Kim-
dc.contributor.googleauthorSang Kyun Sohn-
dc.contributor.googleauthorYoo Hong Min-
dc.contributor.googleauthorJong-Ho Won-
dc.contributor.googleauthorInho Kim-
dc.contributor.googleauthorHwi-Joong Yoon-
dc.contributor.googleauthorJae Hoon Lee-
dc.contributor.googleauthorDeog-Yeon Jo-
dc.contributor.googleauthorYoung Don Joo-
dc.contributor.googleauthorChul Won Jung-
dc.contributor.googleauthorKyoo-Hyung Lee-
dc.identifier.doi10.1093/jjco/hyq007-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01407-
dc.relation.journalcodeJ01207-
dc.identifier.eissn1465-3621-
dc.identifier.pmid20185460-
dc.contributor.alternativeNameMin, Yoo Hong-
dc.contributor.affiliatedAuthorMin, Yoo Hong-
dc.citation.volume40-
dc.citation.number6-
dc.citation.startPage556-
dc.citation.endPage566-
dc.identifier.bibliographicCitationJAPANESE JOURNAL OF CLINICAL ONCOLOGY, Vol.40(6) : 556-566, 2010-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.